business newsBest Stocks: All Biotech All the Time
By
StateOfTheMarkets.com
Mar 18, 2013 10:15 am
This week's "10.0 report" is dominated by biotech names and includes one "buy" rating and two "accumulate" ratings.
PRINT
-
Stay Connected
-
-
-
-
At StateoftheMarkets.com, we focus our attention on the top-rated stocks of the market for a few simple reasons. The top stocks have the best earnings strength. The top stocks have strong fundamentals. The top stocks are also in the top-ranked industry groups. So from our perspective, the top stocks put the odds in your favor before you ever enter a buy order. So, why would anyone invest/trade in anything else?
Listed below are five companies that made our "10.0 Stocks Report" this week.
“10.0 Stocks” For the Week of March 18, 2013:
Company: Arena Pharmaceuticals (NASDAQ:ARNA)
Sector: Health Care
Industry: Biotech
Stock Rating: 10.0
Current Rating: Buy
Trading Stop: Close Below $7.79
Company: Pharmacyclics Inc (NASDAQ:PCYC)
Sector: Health Care
Industry: Biotech
Stock Rating: 10.0
Current Rating: Accumulate here and on pullbacks
Trading Stop: Close Below $84.89
Company: Onyx Pharmaceuticals (NASDAQ:ONXX)
Sector: Health Care
Industry: Biotech
Stock Rating: 10.0
Current Rating: Accumulate
Trading Stop: Close Below $79.89
Company: Gilead Sciences (NASDAQ:GILD)
Sector: Health Care
Industry: Biotech
Stock Rating: 10.0
Current Rating: Hold
Trading Stop: Close Below $42.89
Company: Isis Pharmaceuticals (NASDAQ:ISIS)
Sector: Health Care
Industry: Biotech
Stock Rating: 10.0
Current Rating: Hold
Trading Stop: Close Below $16.49
The StateoftheMarkets “Top Stock” Rating:
The TopStock Rating indicates the combined score of our proprietary Earning Strength and Company Performance models. The rating scale is 0 - 10 with 10 being the highest.
Current Rating
The Current Rating is designed to let readers know what we would do now if we did NOT currently hold the position.
This article by David Moenning was originally published on StateoftheMarkets.com
Below, find some more great content from David Moenning and StateoftheMarkets.com:
Does The Dow's Winning Streak Mean Anything?
What Could Go Wrong?
Beliefs, Knowings and Lessons Learned
Follow on Twitter: @StateDave
Listed below are five companies that made our "10.0 Stocks Report" this week.
“10.0 Stocks” For the Week of March 18, 2013:
Company: Arena Pharmaceuticals (NASDAQ:ARNA)
Sector: Health Care
Industry: Biotech
Stock Rating: 10.0
Current Rating: Buy
Trading Stop: Close Below $7.79
Company: Pharmacyclics Inc (NASDAQ:PCYC)
Sector: Health Care
Industry: Biotech
Stock Rating: 10.0
Current Rating: Accumulate here and on pullbacks
Trading Stop: Close Below $84.89
Company: Onyx Pharmaceuticals (NASDAQ:ONXX)
Sector: Health Care
Industry: Biotech
Stock Rating: 10.0
Current Rating: Accumulate
Trading Stop: Close Below $79.89
Company: Gilead Sciences (NASDAQ:GILD)
Sector: Health Care
Industry: Biotech
Stock Rating: 10.0
Current Rating: Hold
Trading Stop: Close Below $42.89
Company: Isis Pharmaceuticals (NASDAQ:ISIS)
Sector: Health Care
Industry: Biotech
Stock Rating: 10.0
Current Rating: Hold
Trading Stop: Close Below $16.49
The StateoftheMarkets “Top Stock” Rating:
The TopStock Rating indicates the combined score of our proprietary Earning Strength and Company Performance models. The rating scale is 0 - 10 with 10 being the highest.
Current Rating
The Current Rating is designed to let readers know what we would do now if we did NOT currently hold the position.
Strong Buy: Our favorite position. We would be willing to buy a full position at current levels.
Buy: We would be willing to buy at current levels.
Accumulate: We would be willing to take a "starter position" (25% - 33% of the full position) at current levels. However, we would not want to buy a full position at the current time and we would look to add to our "starter position" on weakness.
Hold: We prefer to hold our position at the current levels, but we would not be buyers at this time.
Sell: We are not happy with this position and are looking for an exit point.
Buy: We would be willing to buy at current levels.
Accumulate: We would be willing to take a "starter position" (25% - 33% of the full position) at current levels. However, we would not want to buy a full position at the current time and we would look to add to our "starter position" on weakness.
Hold: We prefer to hold our position at the current levels, but we would not be buyers at this time.
Sell: We are not happy with this position and are looking for an exit point.
This article by David Moenning was originally published on StateoftheMarkets.com
Below, find some more great content from David Moenning and StateoftheMarkets.com:
Does The Dow's Winning Streak Mean Anything?
What Could Go Wrong?
Beliefs, Knowings and Lessons Learned
Follow on Twitter: @StateDave
No positions in stocks mentioned.
Daily Recap
Everything you need to know for the next trading day.
Trading Radar (weekly)
Your road map to all the events that will effect financial markets in the week ahead.
Name
Email
*
Phone
* required field
